Navigation Links
Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
Date:6/20/2016

IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody discovery, and immuno-oncology research, announced a collaboration with Notable Labs to further the development of a predictive personalized medicine platform.

Notable Labs helps oncologists identify effective therapies that they can prescribe today by testing them on a patient’s own cells. This approach promises tailored treatment options fast enough for doctors to put to use. By testing a broad set of drugs and drug combinations, Notable Labs is able to functionally profile cancer cells, which leads to a better understanding of the biological mechanisms of the patient’s cancer. Providing this information to physicians can improve treatment outcomes while reducing side effects.

Notable Labs will utilize IntelliCyt’s iQue® Screener PLUS platform in a fully automated, high-throughput laboratory to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Prioritized treatment options will be highlighted in reports to clinicians using Notable Lab’s screening process with IntelliCyt’s immune-profiling technology.

The IntelliCyt iQue Screener platform, an integrated instrument, software and reagent system, offers a proprietary high-throughput sampling capability that enables the rapid assessment of cells and beads in suspension in 96-, 384-, and 1536-well plates. In addition to the fastest plate processing speed in the industry today for this type of analysis, miniaturization of the assay is possible to save reagent cost and conserve precious samples. Additionally, high content, multiplex readouts are generated on each individual cell or bead via the flow cytometry-based detection system. Data analysis and visualization using ForeCyt® software, provides unique insights into the complex biology of disease.

“IntelliCyt is expanding into the personalized medicine field by leveraging our high throughput, immune-profiling capabilities,” said Janette Phi, Chief Business Officer of IntelliCyt. “We are excited to collaborate with Notable Labs in this transformational path of enabling potentially life-saving therapies.”

“The iQue Screener PLUS offers deeper insights into which treatments target cancer cells while sparing a patient’s healthy cells”, said Matt De Silva, CEO of Notable Labs. “High-throughput flow cytometry provides us with new capabilities to observe real-time drug sensitivity for individual patients on a single cell level.”

About Notable Labs
Our mission is to change the way cancer is treated, which starts with putting patients first. Combining FDA-approved treatment options with laboratory automation and data science, we’ve built a service to help oncologists identify effective therapies that they can prescribe today. For more information, please visit http://www.notablelabs.com.

About IntelliCyt
IntelliCyt Corporation manufactures and sells instrumentation, software and reagents that facilitate the study of cells and their components to gain a better understanding of normal and disease processes. This information speeds the discovery and development of new drugs and provides new insight for the diagnosis of diseases. IntelliCyt’s products are used worldwide throughout the pharmaceutical and biotechnology industries and in nonprofit research labs. For more information, please visit http://www.intellicyt.com.

# # #

Read the full story at http://www.prweb.com/releases/2016/06/prweb13493909.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Fumio Hirakawa has been awarded with the notable Golden A' Design Award
2. Massachusetts General Hospital Enters Into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
3. Molecular Imaging of Colorado Joins Integrated Diagnostic Centers’ Denver Radiology Network
4. AstraZeneca Enters into an Agreement with IntelliCyt for the Development of High Throughput Biology Applications
5. Arrowhead Health Centers at the Forefront of Pain Management with Use of Regenerative Cell-based Therapies to Treat Chronic Pain
6. Genisphere Enters Collaborative Research Agreement with the University of Pennsylvania
7. Bionik Laboratories Enters into Merger Agreement to Acquire Interactive Motion Technologies, Inc. (IMT)
8. Trovagene Enters into Preferred Provider Agreement with Three Rivers Provider Network
9. Trovagene Enters into Preferred Provider Agreement with Fortified Provider Network
10. Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform
11. F-star Enters Into Collaborative Discovery & Development Agreement With AbbVie for Bispecific Antibodies in Immuno-oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):